The Centers for Medicare & Medicaid Services Friday issued a national decision to cover diagnostic laboratory tests using next generation sequencing for certain Medicare patients with advanced cancer. “These tests can help doctors consult with patients about more targeted care or enrollment in a clinical trial,” said CMS Chief Medical Officer Kate Goodrich, M.D. “The expanded coverage in this final [national coverage determination] now includes additional tests for relapsed, refractory and earlier stage III cancers to aid in the treatment of these cancer patients.”

Related News Articles

Headline
The Centers for Medicare…
Headline
The AHA today responded to a RAND Corporation study that found that certain prices paid to hospitals by private health plans are high relative to Medicare and…
Headline
A federal district court judge yesterday ruled that the Department of Health and Human Services would get "first crack at crafting appropriate remedial…
Headline
The Centers for Medicare…
Headline
Reps. Rosa DeLauro, D-Conn., and Jan Schakowsky, D-Ill., this week introduced the Medicare for America Act, legislation that would create a national health…
Headline
Establishing a single-payer system would be a major undertaking that would involve substantial changes in the sources and extent of coverage, provider payment…